Testing a new heart failure and kidney treatment combo
Treatments studied
Part of Heart & circulation clinical trials.
This study tests a new combination of two medicines (balcinrenone and dapagliflozin) for people with heart failure and reduced kidney function. The goal is to see if this combination helps improve heart and kidney health better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with heart failure that causes symptoms (like shortness of breath or fatigue)
- You have had a heart failure-related hospital stay or urgent care visit in the last 6 months
- Your kidney function (eGFR) is between 20 and 60 (moderately to severely reduced)
- Your blood NT-proBNP level is above 300 (or above 600 if you have an irregular heart rhythm called atrial fibrillation)
- You are not currently taking a medication known as an MRA (like spironolactone or eplerenone)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two medications (balcinrenone and dapagliflozin) to help protect your kidneys if you have moderate-to-severe chronic kidney disease. The trial evaluates whether this combination slows kidney damage and improves kidney health.
This trial tests a medication called finerenone to see if it helps people hospitalized for heart failure live longer and have fewer heart-related problems. It may be an option for those with a certain type of heart failure where the heart's pumping strength is mildly reduced or normal.
This study is testing two investigational drugs, balcinrenone and dapagliflozin, in people with kidney failure who are on hemodialysis. The purpose is to see how your body processes these drugs when you are on dialysis, and to make sure they are safe.
This trial tests a new treatment for people with heart failure and severely reduced kidney function. It aims to see if the treatment can help protect both the heart and kidneys.
This trial tests if combining baxdrostat with dapagliflozin helps protect kidney function and reduce heart risks in people with chronic kidney disease and high blood pressure. It's for adults who are already taking standard blood pressure medications.
This trial tests a medication called Finerenone to see if it can improve heart structure and function in people with both diabetic kidney disease and heart failure. If you have type 2 diabetes, kidney problems, and heart failure with preserved pumping function, this study may explore a new treatment option for you.
Hear when a new Heart Failure and Impaired Kidney Function trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.